COVID-19 mRNA Vaccines



What Clinic Personnel Need to Know

| | Pfizer-BioNTech | Moderna |
|---|--|---|
| Product | Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) | Moderna COVID-19 Vaccine (mRNA-1273) |
| Vaccine type | mRNA (messenger RNA) | mRNA (messenger RNA) |
| Age indication | 16 years of age and older | 18 years of age and older |
| Basic information | CDC Resources: Pfizer-BioNTech COVID-19 Overview www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html | CDC Resources: Moderna COVID-19 Overview www.cdc.gov/vaccines/covid-19/info-by-product/ moderna/index.html |
| | ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine www.cdc.gov/mmwr/volumes/69/wr/mm6950e2. htm?s_cid=mm6950e2_w | ACIP Interim Recommendation for Use of Moderna COVID-19 Vaccine www.cdc.gov/mmwr/volumes/69/wr/mm695152e1. htm?s_cid=mm695152e1_w |
| | Pfizer-BioNTech Resources: Pfizer-BioNTech COVID-19 vaccine website www.cvdvaccine-us.com | Moderna Resources: Moderna COVID-19 vaccine website www.modernatx.com/covid19vaccine-eua/providers/ |
| Emergency Use Authorization (EUA) | For Providers www.fda.gov/media/144413/download | For Providers www.fda.gov/media/144637/download |
| factsheets Required to be given to recipients in place of a Vaccine Information Statement (VIS) | For Recipients and Caregivers English www.fda.gov/media/144414/download Translations www.fda.gov/emergency-preparedness-and-response/ coronavirus-disease-2019-covid-19/pfizer-biontech- covid-19-vaccine | For Recipients and Caregivers English www.fda.gov/media/144638/download Translations www.fda.gov/emergency-preparedness-and-response/ coronavirus-disease-2019-covid-19/moderna-covid- 19-vaccine |
| Presentation | Frozen liquid concentrate, no preservative Multidose vial, at least 5 doses/vial* * Some syringe types may be able to draw up to 6–7 full doses per vial, which is acceptable. Never combine vaccine from more than 1 vial to make a dose. | Frozen liquid, no preservative Multidose vial, at least 10 doses/vial* * Some syringe types may be able to draw up 11 full doses per vial, which is acceptable. Never combine vaccine from more than 1 vial to make a dose. |
| Packaging | 195 vials/tray (975 doses) 1–5 trays per shipper Each tray: 9" x 9" x 1.6" | • 10 vials/carton (100 doses) • Each carton: 2" x 2" x 5-3/8" |
| Minimum shipment | 975 doses (195 multidose vials) | 100 doses (10 multidose vials) |

CONTINUED ON THE NEXT PAGE







| | Pfizer-BioNTech | Moderna |
|----------------------|---|--|
| Storage and handling | SHIPPING Shipped at -80°C to -60°C (-112°F to -76°F) | SHIPPING Shipped at -25°C to -15°C (-13°F to 5°F) |
| | STORAGE (protect from light during storage) Frozen: -80°C to -60°C (-112°F to -76°F) In "ultracold" temperature freezer • Up to 6 months In Pfizer thermal shipper with dry ice • Up to 30 days if following Pfizer instructions for dry ice replenishment and # of openings allowed/per day Thermal Shipping Container Dry Ice Replenishment Instructions www.cvdvaccine-us.com/images/pdf/DryIce Replenishment.pdf Refrigerated: 2° to 8°C (36° to 46°F) • Unopened vial: up to 5 days (120 hours)/ must discard after 120 hours • Unopened vial: up to 2 hours at room temperature (up to 25°C [77°F]) • Punctured vial: up to 6 hours in refrigerator or at room temperature (2° to 25°C [36° to 77°F]) • Thawed vaccine cannot be refrozen CDC Resources: Storage and Handling Summary (Pfizer) www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/storage-summary.pdf Ultracold Vaccine Storage Temperature Log CELSIUS www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/temp-log-ultra-cold-storage-celsius.pdf FAHRENHEIT www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/temp-log-ultra-cold-storage-fahrenheit.pdf Refrigerator Vaccine Storage Temperature Log CELSIUS www.cdc.gov/vaccines/covid-19/downloads/refrigerator-storage-logger-celsius.pdf FAHRENHEIT www.cdc.gov/vaccines/covid-19/downloads/refrigerator-storage-logger-celsius.pdf FAHRENHEIT www.cdc.gov/vaccines/covid-19/downloads/refrigerator-storage-logger-fahrenheit.pdf Pfizer Resource: | Shipped at -25°C to -15°C (-13°F to 5°F) STORAGE (protect from light during storage) Frozen: -25°C to -15°C (-13°F to 5°F) • Up to 6 months • If storing in freezer with other routinely recommended vaccines, carefully adjust freezer temperature range to THIS vaccine • Do NOT store on dry ice Refrigerated: 2°C to 8°C (36°F to 46°F) • Unopened vial: up to 30 days • Unopened vial: up to 12 hours at room temperature (up to 25°C [77°F]) • Punctured vial: up to 6 hours in refrigerator or at room temperature (2° to 25°C [36° to 77°F]) • Thawed vaccine cannot be refrozen CDC Resources: Storage and Handling Summary (Moderna) www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/storage-summary.pdf Freezer Vaccine Storage Temperature Log CELSIUS www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/temp-log-freezer-storage-celsius.pdf FAHRENHEIT www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/temp-log-freezer-storage-fahrenheit.pdf Refrigerator Vaccine Storage Temperature Log CELSIUS www.cdc.gov/vaccines/covid-19/downloads/refrigerator-storage-logger-celsius.pdf FAHRENHEIT www.cdc.gov/vaccines/covid-19/downloads/refrigerator-storage-logger-celsius.pdf FAHRENHEIT www.cdc.gov/vaccines/covid-19/downloads/refrigerator-storage-logger-fahrenheit.pdf Moderna Resource: Storage and handling guidance www.modernatx.com/covid19vaccine-eua/providers/ storage-handling |

CONTINUED ON THE NEXT PAGE

Storage and handling guidance www.cvdvaccine-us.com/product-storage-and-dry-ice



| 440 | | | | |
|-----|---|---|---|---|
| | 1 | | 7 | |
| | | 1 | | _ |

| | Pfizer-BioNTech | Moderna |
|--------------------------------|---|---|
| Expiration date | CDC Resource: COVID-19 expiration date tracking tool www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/ downloads/expiration-tracker.pdf | CDC Resource: COVID-19 expiration date tracking tool www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/ downloads/expiration-tracker.pdf |
| | | Moderna Resource: Vaccine expiration date look-up tool (Moderna) www.modernatx.com/covid19vaccine-eua/providers/ vial-lookup |
| Preparation and administration | | |
| Thawing | Vaccine may be thawed in refrigerator or at room temperature | Vaccine may be thawed in refrigerator or at room temperature |
| | Refrigerator: 2°C to 8°C (36°F to 46°F) • 25–195 vials may take 2 to 3 hours to thaw | Refrigerator: 2°C to 8°C (36°F to 46°F) • 2.5 hours to thaw |
| | Fewer vials will take less time Room temperature: up to 25°C (77°F) Thaw between 30 minutes and 2 hours Unopened vials may be kept at room temperature for up to 2 hours. Mix with diluent within 2 hours or return to refrigerator Once diluted, use or discard within 6 hours | Room temperature: 15°C to 25°C (59°F to 77°F) Thaw for 1 hour Unopened vials may be kept at room temperature for up to 12 hours Once punctured, use or discard within 6 hours Thawed vaccine cannot be refrozen |
| | Thawed vaccine cannot be refrozen | |
| Dilution | Dilute vial of vaccine concentrate with 1.8 mL preservative-free* 0.9% sodium chloride (normal saline) *do not use bacteriostatic normal saline • Thaw before dilution, invert gently to mix • Do not shake vial (discard if shaken) • Must use diluted vaccine within 6 hours or discard | NONE |
| | CDC Resources: Vaccine preparation: mixing diluent and vaccine www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/ downloads/diluent-poster.pdf | |
| Needle gauge and length | 22–25 gauge, 1 – 1½" | 22–25 gauge, 1 – 1½" |
| Dose | 0.3 mL | 0.5 mL |
| Route | Intramuscular (IM) | Intramuscular (IM) |

CONTINUED ON THE NEXT PAGE





| | Pfizer-BioNTech | Moderna | |
|---|---|---|--|
| Preparation and administration continued | | | |
| Dosing regimen | 2 doses, separated by 21 days (3 weeks) Both doses must be Pfizer-BioNTech vaccine Schedule dose #2 at least 21 days after dose #1. Doses administered up to 4 days early are still considered valid; however, do not routinely schedule at less than 21 days. If dosing interval exceeds 21 days, give ASAP. Do not restart series. | 2 doses, separated by 28 days (1 month) Both doses must be Moderna vaccine Schedule dose #2 at least 28 days after dose #1. Doses administered up to 4 days early are still considered valid; however, do not routinely schedule at less than 28 days. If dosing interval exceeds 28 days, give ASAP. Do not restart series. | |
| | CDC Resources: Preparation and Administration Summary (Pfizer) www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/ downloads/prep-and-admin-summary.pdf | CDC Resources: Preparation and Administration Summary (Moderna) www.cdc.gov/vaccines/covid-19/info-by-product/ moderna/downloads/prep-and-admin-summary.pdf | |
| | Standing Orders Template (Pfizer) www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/ downloads/standing-orders.pdf | Standing Orders Template (Moderna) www.cdc.gov/vaccines/covid-19/info-by-product/ moderna/downloads/standing-orders.pdf | |
| Contraindications and precautions | Contraindication: Severe allergic reaction (e.g., anaphylaxis) or any non-severe immediate allergic (e.g., hives, swelling, or wheezing within 4 hours) to a previous dose or any comvaccine, including polyethylene glycol (PEG) or polysorbate (a related chemical Precautions: | | |
| | CDC Resources: Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html APPENDIX A: Triage of persons presenting for mRNA COVID-19 vaccination APPENDIX B: Ingredients included in Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/anaphylaxis-management.html | | |
| Recommended observation time post-vaccination | Persons with a history of an immediate allergic reaction of any severity to any other vaccine or injectable therapy or a history of anaphylaxis (from any cause) – 30 minutes All other persons – 15 minutes | | |
| Adverse event reporting | | rs are required to report: vaccine administration tisystem inflammatory syndrome (MIS-C), and | |
| | Patient self-reporting (voluntary): • v-safe (smartphone-based after vaccination health checker): www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html continued on the next page ▶ | | |



| 46 | |
|------|--|
| 07/1 | |

| | Pfizer-BioNTech | Moderna |
|---|---|---|
| Post-injection symptoms / adverse events (as reported during clinical trials) | Most symptoms mild-moderate, onset within 1–2 days, and resolve in 1–2 days. Frequency higher for dose 2 and for younger recipients (italics=most commonly observed reactions) Injection site: pain, swelling, redness | Most symptoms mild-moderate, onset within 1–2 days, and resolve in 1–2 days. Frequency higher for dose 2 and for younger recipients (italics=most commonly observed reactions) Injection site: pain, swelling, redness |
| | (80–89% reported one or more) | (84–91% reported one or more) |
| | Systemic: fatigue, headache, muscle pain, chills, fever, joint pain (71–83% reported one or more) | Systemic: fatigue, headache, muscle pain, joint ache, chills (72–82% reported one or more) |
| | CDC Resources: Reactions and adverse events (Pfizer-BioNTech) www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/ reactogenicity.html | CDC Resources: Reactions and adverse events (Moderna) www.cdc.gov/vaccines/covid-19/info-by-product/ moderna/reactogenicity.html |
| Codes | | |
| Product | CPT - 91300 * *American Medical Association www.ama-assn.org/system/files/2020-11/covid- 19-immunizations-appendix-q-table.pdf | CPT - 91301 * *American Medical Association www.ama-assn.org/system/files/2020-11/ covid-19-immunizations-appendix-q-table.pdf |
| | NDC 10/11 (dose level/unit of use) 59267-1000-1 59267-1000-01 | NDC 10/11 (dose level/unit of use) 80777-273-10 80777-0273-10 |
| | CVX – 208 | CVX – 207 |
| Administration | • 1st dose: 0001A • 2nd dose: 0002A | • 1st dose: 0011A • 2nd dose: 0012A |
| Medicare/CMS | Medicare Part B Payment for COVID-19 Vaccinesduring the Public Health Emergency www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies | |
| Frequently Asked Questions FAQs for Healthcare Professionals (CDC) www.cdc.gov/vaccines/covid-19/hcp/faq.html Ask the Experts (IAC) www.immunize.org/askexperts/experts_cov.asp | | |
| | | |
| Manufacturer contact | Main website: www.cvdvaccine.com | Main website: www.modernatx.com |
| (while under EUA) | General product inquiries: 877-829-2619 Medical information: 800-438-1985 www.pfizermedicalinformation.com/en-us/pfizer-bion-tech-covid-19-vaccine | Customer service: 866-MODERNA (866-663-3762) |
| | Customer service: 800-879-3477 | |